Home Cart Sign in  
Chemical Structure| 95041-90-0 Chemical Structure| 95041-90-0

Structure of Erianin
CAS No.: 95041-90-0

Chemical Structure| 95041-90-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Erianin is a compound with antipyretic and analgesic effects that can inhibit indoleamine 2,3-dioxygenase (IDO)-induced tumor angiogenesis, making it suitable for anti-tumor research.

Synonyms: NSC 613744

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Erianin

CAS No. :95041-90-0
Formula : C18H22O5
M.W : 318.36
SMILES Code : COC1=C(C=C(C=C1)CCC2=CC(OC)=C(C(OC)=C2)OC)O
Synonyms :
NSC 613744
MDL No. :MFCD06795132
InChI Key :UXDFUVFNIAJEGM-UHFFFAOYSA-N
Pubchem ID :356759

Safety of Erianin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HCT116 (KRAS mutant) 12.5, 25, 50 nM 24 hours Inhibited constitutive activation of MAPK signaling pathway PMC9986241
A375 (BRAF V600E mutant) 12.5, 25, 50 nM 24 hours Inhibited constitutive activation of MAPK signaling pathway PMC9986241
MG63.2 cells 0, 10, 25, 50, 100 nM 24, 48, 72 hours Erianin inhibited the proliferation of MG63.2 cells in a time and dose-dependent manner with IC50 values of 88.69 nM (24 h), 44.26 nM (48 h), and 17.20 nM (72 h). PMC5143374
143B cells 0, 10, 25, 50, 100 nM 24, 48, 72 hours Erianin inhibited the proliferation of 143B cells in a time and dose-dependent manner with IC50 values of 58.19 nM (24 h), 40.97 nM (48 h), and 26.77 nM (72 h). PMC5143374
NCI-H1299 (H1299) 200, 100, 50, 25, 12.5, and 0 nM 24 hours To evaluate the effect of Erianin on lung cancer cell viability. Erianin significantly reduced the survival rate of both cell lines, with IC50 values of 61.33 nM for H460 cells and 21.89 nM for H1299 cells. PMC11899589
NCI-H460 (H460) 200, 100, 50, 25, 12.5, and 0 nM 24 hours To evaluate the effect of Erianin on lung cancer cell viability. Erianin significantly reduced the survival rate of both cell lines, with IC50 values of 61.33 nM for H460 cells and 21.89 nM for H1299 cells. PMC11899589
Human immortalized keratinocyte (HaCaT) 30 nM 24 hours To evaluate the anti-proliferative and pro-apoptotic effects of E/DMSNs on HaCaT cells. Results showed that E/DMSNs had stronger anti-proliferative and pro-apoptotic effects than free erianin. PMC7104482
HEK293T cells 5 nM 6 hours To evaluate the effect of ACBI1 on SMARCA4 protein levels in HEK293T cells, results showed that ACBI1 treatment led to a reduction in SMARCA4 protein levels. PMC8564113
Human Retinal Vascular Endothelial Cells (HRVECs) 10-100 nM 24 hours Erianin significantly inhibited the proliferation, migration, tube formation, and adhesion of hypoxia-induced HRVECs in a concentration-dependent manner. The inhibitory effect on cell proliferation and tube formation was more pronounced in the collagen-cultured group. PMC8787642
SK-MEL-2 (NRAS mutant) 12.5, 25, 50 nM 24 hours Inhibited constitutive activation of MAPK signaling pathway PMC9986241
THP-1 cells 5 nM 6 hours Assess migration capability of THP-1 cells PMC8564113

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOD-SCID mice A375 (BRAF V600E mutant) and SK-MEL-2 (NRAS mutant) cell-derived xenograft model Oral gavage 50 mg/kg Once daily, tumor volume was monitored twice per week Inhibited tumor growth and reduced tumor volume and weight PMC9986241
BALB/c nude mice H460 cell xenograft model Intraperitoneal injection 100 mg/kg Once daily for 15 days Erianin notably suppressed tumor growth PMC7205607
BALB/c-nu mice Osteosarcoma xenograft model Intraperitoneal injection 2 mg/kg Every other day for seven times Erianin significantly inhibited tumor growth with little organ-related toxicity. PMC5143374
Nude mice Lung cancer-bearing nude mice model Intraperitoneal injection 50 mg/kg, 100 mg/kg, and 200 mg/kg Every 2nd day for 18 days To evaluate the inhibitory effects of Erianin on lung cancer growth in vivo. Medium and high doses of Erianin significantly inhibited tumor growth without significant effects on body weight. PMC11899589
C57BL/6 mice MSU-induced peritonitis and gouty arthritis models Intraperitoneal injection 5 mg/kg Single injection, lasting 12 hours Erianin exhibited dose-dependent inhibitory effects on MSU-induced IL-1β and IL-18 production and neutrophil migration but had no effect on TNF-α production. PMC8564113
Zebrafish (adult and embryos) Hypoxia-induced retinopathy model Embryo medium (embryo model) and intravitreal injection (adult model) 100-1000 nM Embryo model: 4 days; Adult model: 7 days Erianin significantly reduced hypoxia-induced retinal angiogenesis in zebrafish in a concentration-dependent manner. In the adult model, the inhibitory effects on vascular branch points, sprouts, and vascularization areas were more pronounced. PMC8787642

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.14mL

0.63mL

0.31mL

15.71mL

3.14mL

1.57mL

31.41mL

6.28mL

3.14mL

 

Historical Records

Categories